Notícias e Atividades da Hummingbird Bioscience

Veja o organograma con seus 23 executivos principais

Biografias mais buscadas da Hummingbird Bioscience

• Piers Ingram, Chief Executive Officer and Executive Director
• Kenneth Harrison, Director
• Victor Tong, Director

Recentes movimentos de executivos em Hummingbird Bioscience

• Angèle Maki, Chief Business Officer, deixou a Companhia  (Notícia publicada em 4 de dezembro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Hummingbird Bioscience.

Hummingbird Bioscience possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Hummingbird Bioscience

• Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies | Hummingbird Bioscience
• News – 2025 | Hummingbird Bioscience
• News – 2019 | Hummingbird Bioscience
• News – 2024 | Hummingbird Bioscience
• Journal for ImmunoTherapy of Cancer: P477 HMBD-002-V4: A novel anti-VISTA antibody that uniquely binds murine and human VISTA and potently inhibits tumor growth by remodeling the immunosuppressive tumor microenvironment | Hummingbird Bioscience
• Hummingbird Bioscience Publishes Preclinical Data Demonstrating Therapeutic Potential of HMBD-002 in VISTA-expressing Cancers | Hummingbird Bioscience
• Journal for ImmunoTherapy of Cancer: Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner. | H
• New biotech facility Hummingbird Bioscience opens | Video
• Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies - Hummingbird Bioscience
• Hummingbird Bioscience Publishes Preclinical Data Demonstrating Therapeutic Potential of HMBD-002 in VISTA-expressing Cancers - Hummingbird Bioscience
• View more press releases Close

Redes sociais sobre Hummingbird Bioscience

• Hummingbird Bioscience na Wikipedia, Google News e Yahoo Finance
• Hummingbird Bioscience na LinkedIn, X (Twitter) e YouTube